NASDAQ:OVID Ovid Therapeutics Q1 2026 Earnings Report $2.45 -0.02 (-0.81%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast Ovid Therapeutics EPS ResultsActual EPS-$0.12Consensus EPS -$0.12Beat/MissMet ExpectationsOne Year Ago EPSN/AOvid Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$0.06 millionBeat/MissN/AYoY Revenue GrowthN/AOvid Therapeutics Announcement DetailsQuarterQ1 2026Date5/12/2026TimeBefore Market OpensConference Call DateTuesday, May 12, 2026Conference Call Time7:00AM ETUpcoming EarningsOvid Therapeutics' Q2 2026 earnings is estimated for Wednesday, August 12, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, August 11, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Ovid Therapeutics Earnings HeadlinesOvid Therapeutics: Advancing Seizure Pipeline and Neuropsychiatric Programs Support Buy Rating and Unchanged $4 Price TargetMay 26 at 6:51 AM | tipranks.comHead-To-Head Survey: Ovid Therapeutics (NASDAQ:OVID) versus Sernova Biotherapeutics (OTCMKTS:SEOVF)May 23 at 4:02 AM | americanbankingnews.comRead this warning immediatelyPorter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.May 26 at 1:00 AM | Porter & Company (Ad)Former Ovid CEO Dr. Jeremy Levin’s rallying cry for biotechMay 15, 2026 | finance.yahoo.comWe're Hopeful That Ovid Therapeutics (NASDAQ:OVID) Will Use Its Cash WiselyMay 14, 2026 | finance.yahoo.comOvid Therapeutics Reports Business Updates and First Quarter 2026 Financial ResultsMay 12, 2026 | globenewswire.comSee More Ovid Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ovid Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ovid Therapeutics and other key companies, straight to your email. Email Address About Ovid TherapeuticsOvid Therapeutics (NASDAQ:OVID) is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need. The company’s lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome. OV101 has demonstrated proof-of-concept activity in early clinical studies, and ongoing trials aim to further characterize its safety and efficacy profiles. In parallel, Ovid is advancing OV935, a small-molecule inhibitor targeting specific kinase pathways implicated in CDKL5 deficiency disorder, a severe form of early-onset epilepsy. To support its global development strategy, Ovid has established strategic collaborations with industry partners. A notable agreement grants regional rights for OV935 to a leading pharmaceutical company for select Asian markets. The company maintains additional research partnerships to broaden its preclinical pipeline and leverage external expertise in rare disease biology and regulatory science. Ovid Therapeutics completed its initial public offering on the Nasdaq market in 2018 and continues to engage with regulatory authorities to advance its clinical programs toward potential approval. The organization is led by a management team with deep experience in neuroscience drug discovery and development, supported by a board of directors comprised of seasoned professionals in biopharma innovation and commercialization.View Ovid Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AutoZone's Pullback Sets Up a Long-Term Buying OpportunityAST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in FocusPowerhouse Williams-Sonoma Heading to Fresh Highs in 2026Why BJ’s Wholesale Club Stock Could Be Ready for a ReboundRocket Companies Turns Around, But Mortgage Risk RemainsAfter NVIDIA, Broadcom's Earnings Are Next—Here's What to WatchRoss Stores Earnings Beat Sends Stock To New Highs Upcoming Earnings Marvell Technology (5/27/2026)PDD (5/27/2026)Synopsys (5/27/2026)Bank Of Montreal (5/27/2026)Bank of Nova Scotia (5/27/2026)Salesforce (5/27/2026)Snowflake (5/27/2026)Autodesk (5/28/2026)Costco Wholesale (5/28/2026)Canadian Imperial Bank of Commerce (5/28/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
